Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 15.1% in October

by · The Cerbat Gem

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 21,300 shares, an increase of 15.1% from the October 15th total of 18,500 shares. Based on an average daily volume of 16,500 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Akari Therapeutics in a research note on Sunday, November 10th. They set a “sell” rating on the stock.

View Our Latest Research Report on Akari Therapeutics

Akari Therapeutics Trading Down 6.7 %

NASDAQ:AKTX opened at $2.08 on Friday. The company has a fifty day moving average of $2.75 and a 200 day moving average of $2.84. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40.

Akari Therapeutics Company Profile

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

Featured Stories